retatrutide mechanism of action triple agonist glp-1 gip glucagon How Does Work? Explained retatrutide triple agonist glp-1 gip

Approval for Cardiovascular Risk Reduction Ongoing cardiovascular outcomes trials (CVOT) studies clearly demonstrated that three of the diabetes incretin medications (liraglutide, dulaglutide and semaglutide) and one of the weight loss versions of this class (Wegovy) also reduce cardiovascular disease risk

Viking's Dual Agonist Drug Shows Potential As It Moves Through Trial Process A much smaller firm than Eli Lilly, Viking Therapeutics Inc

GLP-1 Receptor Agonist Market Fierce Pharma, U.S

Zhang J, Tang H, Deng R, Wang N, Zhang Y, Wang Y, et al

GLP-1RA medications are the first pharmacotherapy for obesity with demonstrable cardiovascular benefits and ASCVD risk reduction